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OBJECTIVES We sought to prospectively assess the feasibility and in-hospital efficacy of the PercuSurge
GuardWire temporary balloon-occlusive system for neuroprotection during carotid angio-
plasty and stenting (CAS).
BACKGROUND Carotid angioplasty and stenting harbors a risk of distal embolization. Cerebral protection
devices are currently under clinical investigation.
METHODS Ninety-six consecutive patients with carotid bifurcation disease underwent a total of 102 CAS
procedures with the intention to use the GuardWire for neuroprotection.
RESULTS GuardWire deployment was achieved in 99 procedures performed in 93 patients (97%).
Device failure (n  3) and severe neurologic responses to balloon occlusion of the targeted
carotid artery (n 2) accounted for five additional procedures that were essentially concluded
without neuroprotection, for a total of 94 procedures completed as intended in 88 patients
(92% procedural feasibility rate). Carotid angioplasty and stenting was performed successfully
in 94 patients (100 procedures). There were no in-hospital deaths; but three patients (3.1%)
sustained strokes, and two patients experienced transient ischemic attacks, for a total
periprocedural complication rate of 5.2%. One major stroke occurred with the GuardWire in
place, whereas two minor strokes were observed in patients in whom the device could not be
deployed. Thus, successful neuroprotected CAS without major neurologic events was
achieved in 87 patients (91%).
CONCLUSIONS The GuardWire temporary balloon-occlusive system is feasible as an adjunct to CAS in the
majority of patients. It is associated with a 3.1% rate of major periprocedural neurologic
complications. Adverse neurologic reactions to balloon occlusion may prohibit effective use of
the system in about 2% of patients. (J Am Coll Cardiol 2002;40:890–5) © 2002 by the
American College of Cardiology Foundation
Carotid angioplasty and stenting (CAS) has emerged as an
alternative treatment to endarterectomy in patients with
carotid bifurcation lesions (1–3). Both approaches harbor
the risk of embolic stroke (4–6). In CAS, the incidence of
this potentially disastrous complication still needs to be
established in a sufficiently large number of patients; yet, a
variety of neuroprotective devices are currently being inves-
tigated as possible adjuncts to CAS to prevent embolic
stroke. The first such device available to clinicians is the
PercuSurge GuardWire, which can be used during inter-
ventions at degenerated saphenous vein grafts (7,8) as well
as during carotid interventions (9). Its major component is
a short balloon mounted on a hollow-tube guide wire by
which the balloon can be placed and inflated distal to the
target lesion. Blood flow across the lesion is thus blocked,
and any atheromatous debris liberated during the interven-
tion is prevented from entering the distal circulation. The
present prospective study was designed to assess the device-
specific advantages and disadvantages of GuardWire place-
ment in the cervical vasculature and its short-term efficacy in
preventing neurologic complications during CAS in a
single-center setting.
METHODS
Patients. Between January 1999 and March 2001, 96
consecutive patients (74 males; 68  9 years) underwent
elective CAS at our institution. Use of the GuardWire
device was intended in all patients. Major patient inclusion
criteria were the presence of a carotid bifurcation lesion with
an angiographic diameter stenosis70% (visual estimate) in
symptomatic patients and 80% in asymptomatic patients,
a distal diameter of the target vessel between 4 and 6 mm,
and 40 mm of normal vessel distal to the lesion. Major
exclusion criteria were total occlusion of the contralateral
internal carotid artery (ICA) in the presence of ipsilateral
vertebral or intracranial disease and angiographic evidence
of thrombus at the lesion site, as well as a recent (14 days)
stroke or myocardial infarction. All patients were informed
of the investigational nature of CAS and the intended use of
the GuardWire system and gave written, informed consent.
Pertinent patient characteristics are summarized in Table 1.
Device description. The PercuSurge GuardWire tempo-
rary occlusion and aspiration system (Medtronic AVE,
Santa Rosa, California) has been described in detail previ-
ously (7–9). In short, the three-component system consists
of: 1) a 190- or 300-cm hollow guide wire with an outer
diameter of 0.014 in. or 0.018 in. to which a compliant
distal balloon is attached; 2) a MicroSeal adapter to enable
balloon inflation, “sealing” of the wire to maintain balloon
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pressure after disconnection of the adapter, and balloon
deflation; and 3) the Export aspiration catheter with a
1.1-mm distal lumen diameter.
Clinical protocol. An independent neurologist established
the indication for intervention. The neurologic examination
included a calculation of the National Institutes of Health
(NIH) Stroke Scale and was repeated after the intervention
and before discharge. Patients were discharged with a
regimen of clopidogrel (75 mg/day for 1 month) and aspirin
(100 mg/day).
Procedure. Most patients received clopidogrel (75 mg/day)
and aspirin (100 mg/day) at least three days before the
intervention. In patients who were not premedicated, a
loading dose of clopidogrel (300 mg) and a bolus of
intravenous aspirin (500 mg) were administered before the
intervention. A 100-cm 5F selective “Vitek” catheter (Cook
Inc., Bloomington, Indiana) was used for brachiocephalic
angiography. A 0.035-in. guide wire was then introduced
through the lumen of the Vitek catheter into the external
carotid artery, and the Vitek catheter was subsequently
exchanged for a 6F or 7F long sheath. This was placed in
the common carotid artery, and 70 to 100 IU/kg of heparin
was administered to raise the activated clotting time above
225 s. An angiogram was obtained in the anteroposterior
and lateral views to document cerebral blood flow. After
advancement of the introducer sheath toward the carotid
bifurcation, a magnified “worst view” angiogram of the
lesion was taken.
After testing for integrity, the GuardWire balloon was
fully deflated, introduced into the carotid artery, and ad-
vanced across the lesion. It was positioned at least 4 cm
distal to the stenosis and slowly inflated until the vessel size
was reached. Contrast dye was administered to verify total
blockage of anterograde flow. At this point, atropine (1 mg)
was given to prevent hypotension and bradycardia. A
self-expanding Carotid Wallstent (Boston Scientific, Maple
Grove, Minnesota) was then advanced into the lesion, and
its correct position was checked before release by another
administration of contrast dye, which ran off by way of the
external carotid artery. Lesions were stented either directly
or, in particularly high-grade stenoses, after predilation. All
stents were postdilated with a 5.0-mm or 6.0-mm balloon,
depending on the vessel size. After postdilation, the Export
catheter was advanced toward the GuardWire balloon.
Applying suction, the catheter was advanced and retracted
once or twice between the stent and balloon until 20 to 40
ml of blood and debris were aspirated. Flushing the lesion
site with saline solution was not performed. Finally, the
distal occlusion balloon was deflated, and angiographic
assessments were performed.
End points. End points were evaluated on an intent-to-
treat basis. Feasibility end points were the successful place-
ment of the balloon distal to the lesion, device performance,
and patient tolerance of balloon occlusion. The efficacy end
point was any periprocedural neurologic event, including a
transient ischemic attack (TIA), defined as a neurologic
deficit that resolved without residuals within 24 h; a minor
stroke, defined as a new neurologic deficit that resulted in
slight impairment of neurologic function (speech, motor, or
sensory skills) and either completely resolved within seven
days or caused an increase in the NIH stroke scale of 4;
and a major stroke, defined as a new neurologic deficit that
persisted after seven days and increased the NIH stroke
scale by 4 (10).
Statistics. Exact 95% confidence intervals (CIs) based on
the binomial distribution were calculated for proportions
(11).
RESULTS
Ninety-six patients underwent a total of 102 interventions;
six patients were treated sequentially for bilateral carotid
disease. There were 54 culprit lesions located at the right
internal carotid bifurcation and 48 at the left internal carotid
bifurcation. The median estimated lesion length was 10 mm
(range 4 to 30 mm), and the median estimated angiographic
diameter stenosis was 90% (range 70% to 99%). Forty-seven
lesions in 44 patients (46%) were associated with a history of
neurologic symptoms within the previous six months (TIA
or stroke), whereas 55 lesions in 52 patients (54%) had been
asymptomatic. Figure 1 shows a breakdown of the 102
procedures and associated neurologic events.
Device deployment. The GuardWire balloon was success-
fully deployed in 99 procedures performed in 93 patients
(97%). In two patients, the common carotid artery could not
be accessed, because of an acute offset of the vessel. Both
patients were referred to carotid endarterectomy. In the
third patient who had a distal 360° loop of the left ICA, the
Abbreviations and Acronyms
CAS  carotid angioplasty and stenting
CI  confidence interval
ICA  internal carotid artery
NIH  National Institutes of Health
TIA  transient ischemic attack
Table 1. Patient Characteristics (n  96)
Age (yrs) 68  9
Age 80 yrs 6 (6%)
Males 74 (77%)
Coronary heart disease 53 (55%)
Diabetes 27 (28%)
Hypertension 61 (64%)
Hyperlipidemia 68 (71%)
Smoking (post or current) 58 (60%)
History of recent stroke 8 (8%)
History of recent TIA 36 (38%)
Amaurosis fugax 12 (13%)
Motor-sensory deficits 24 (25%)
Bilateral carotid disease 24 (25%)
Previous intervention at target lesion 2 (2%)
Data are presented as the mean value  SD or number (%) of patients.
TIA  transient ischemic attack.
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GuardWire passed both the lesion and the loop but could
not be advanced cranially enough to safely inflate the
balloon (Fig. 2). The procedure was eventually completed
without neuroprotection, using a standard 0.018-in. guide
wire in exchange for the GuardWire.
Stenting. Stenting was achieved successfully (residual ste-
nosis 30%) in all 100 procedures completed on a catheter
basis in 94 patients. Thus, the stenting failure rate was 2.1%
(95% CI 0.2% to 7.3%). Direct stenting had been performed
in 29 procedures. The median procedure duration and
balloon occlusion times were 60 min (range 30 to 125 min)
and 8 min (range 3.2 to 22.0 min), respectively.
Device failure. Due to leakage of the GuardWire’s valve-
sealing mechanism, balloon pressure was not maintained for
the duration of the intervention in three patients (3.1%; 95%
CI 0.7% to 8.9%). These patients must therefore be con-
sidered as having been treated without neuroprotection.
Vascular complications. In a single patient, a dissection
was noted after balloon deflation at the site of the balloon.
This dissection was covered with another stent. There were
no cases of stent malposition or bail-out stenting.
Balloon “intolerance.” An adverse neurologic response to
occlusion of the ICA that resolved promptly upon balloon
deflation (balloon “intolerance”) was encountered in 5
(5.4%) of 93 patients (95% CI 1.8% to 12.1%). In three
patients, symptoms (clouding of consciousness in 2 and
mild paresis of the contralateral arm in 1) occurred 4, 5, and
6 min after balloon inflation and were tolerated until
completion of the procedure after 7, 7, and 9 min, respec-
tively. One patient, however, went into a coughing parox-
ysm and seizure after postdilation (4.5 min after balloon
inflation), necessitating immediate deflation of the balloon
before aspiration. In another patient, balloon inflation
caused instantaneous loss of consciousness; stenting in this
patient was subsequently performed without neuroprotec-
tion. These last two procedures had to be regarded as
unprotected. They represent 2.2% (95% CI 0.3% to 7.6%) of
patients in whom an adverse neurologic response to balloon
occlusion of the target ICA prevented effective use of the
GuardWire device.
Thus, with a total of eight procedures in which the
GuardWire either could not be deployed (n  3), did not
maintain balloon pressure (n  3), or was not tolerated to
the extent that neuroprotected CAS was achieved (n  2),
94 procedures were completed as intended in 88 patients,
for a procedural feasibility rate of 92% (95% CI 84% to
96%).
Neurologic complications. On an intent-to-treat basis,
periprocedural neurologic complications were observed in
five patients (5.2%; 95% CI 1.7% to 11.7%). There were
three strokes (3.1%) and two TIAs. Two minor strokes
occurred in symptomatic patients, whereas a major stroke
and both TIAs were observed in asymptomatic patients, for
major complication (stroke) rates in symptomatic and
asymptomatic patients of 4.6% (95% CI 0.6% to 15.5%) and
1.9% (95% CI 0.1% to 10.3%), respectively. Both minor
strokes occurred in patients in whom the device could not be
deployed; the major stroke and TIAs were encountered in
patients in whom the device had been in place throughout
the intervention (Table 2). Thus, balloon-protected CAS
could be performed according to the protocol without major
neurologic events in 87 patients, for a procedural success rate
of 91% (95% CI 83% to 96%). The periprocedural rate of
stroke/TIA, even though the device was in place, was 3.4%
(3 of 88 patients; 95% CI 0.7% to 9.6%).
The patient who sustained a major stroke was a 58-year-
old man with severe peripheral artery occlusive disease who
experienced contralateral hemiparesis immediately after the
intervention at an asymptomatic high-grade stenosis of the
right ICA; five weeks after the intervention, left-sided
Figure 1. Breakdown of 102 carotid angioplasty and stenting procedures and associated events.3CEA referred to carotid endarterectomy; Tgt target.
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hypoesthesia and impaired coordination of the left hand and
leg were still present.
Of the minor strokes, one occurred in the patient with a
360° ICA loop (Fig. 2). Attempts to place the GuardWire
appropriately distal to this anatomic abnormality lasted for
about 20 to 25 min and were eventually aborted in favor of
unprotected stenting. Neurologic symptoms related to the
ipsilateral hemisphere were noted within minutes of com-
pletion of the procedure; they comprised weakness of the
right arm and discrete aphasia. Symptoms resolved com-
pletely within a few days.
In another (female) patient, about 90 min was spent in
ultimately futile attempts to cannulate the right common
carotid artery, using both transfemoral and transbrachial
routes. Three hours after termination of the procedure
without any therapeutic intervention, the patient developed
a minor stroke with symptoms (hemiparesis, mild aphasia)
related to the contralateral hemisphere; symptoms resolved
within 48 h.
DISCUSSION
Major findings. This single-center, prospective study of 96
patients showed that placement of the PercuSurge Guard-
Wire distal to a high-grade carotid bifurcation lesion can be
achieved in 97% of patients. However, failure of the balloon
to maintain pressure throughout the intervention (n  3)
and severe neurologic responses to balloon occlusion of the
targeted ICA (n  2) reduced the procedural feasibility rate
to 92% in our patient cohort. There were no deaths. A total
of five periprocedural neurologic complications (5.4%) were
observed, three of which were strokes (3.1%). The strokes
occurred in two symptomatic patients and one asymptom-
atic patient, resulting in major periprocedural complication
rates in these patient subgroups of 4.6% and 1.9%, respec-
tively. Two strokes were encountered in patients in whom
the device could not be deployed, whereas the other stroke
and two TIAs occurred despite per-protocol GuardWire
Figure 2. Cervical radiographs showing (A) the target lesion (thin arrows) and distal loop (thick arrow) in the left internal carotid artery and (B)
furthermost advancement of the GuardWire into this vessel. In panel B, note that, although the wire had passed both the lesion and loop, the distal tip
of the wire (arrow) could not be advanced cranially enough to safely inflate the balloon.
Table 2. Periprocedural Neurologic Complications According to
Procedural Outcome
Procedure Completed
as Intended
(n  88)
Procedure Not
Completed as Intended
(n  8)
Major stroke 1 0
Minor stroke 0 2
TIA 2 0
TIA  transient ischemic attack.
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placement and function. Thus, procedural success (device
placement and stenting without major neurologic events)
was achieved in 87 patients (91%).
Device deployment. Adverse vessel anatomy prohibited
introduction of the device into the common carotid artery in
two patients, one of whom sustained a minor contralateral
stroke. In another patient with a distal ICA loop, the
GuardWire could not be placed distally enough to safely
inflate the balloon, and stenting was performed without
neuroprotection; the patient had a minor ipsilateral stroke.
Neither event appears to be device-specific.
Once the GuardWire balloon is successfully positioned
and inflated, stenting equipment will be advanced over the
wire. Despite blockage of anterograde ICA flow, correct
positioning of the unexpanded stent is still possible through
the injection of a contrast agent, which will drain into the
external carotid artery. However, friction between the bal-
loon and vessel wall during the manipulation of endolumi-
nal equipment may cause a dissection, as observed in one of
our patients.
Device failure. Leakage of the GuardWire’s valve-sealing
mechanism resulted in a gradual loss of balloon pressure
during three procedures; consequently, these were essen-
tially concluded without neuroprotection. The underlying
technical problem has been recognized by the manufacturer
and remedied in the currently available GuardWire Plus
system.
Balloon “intolerance.” A total of five patients experienced
an adverse neurologic response to balloon occlusion that
subsided without residuals upon balloon deflation. In four
patients, symptoms occurred within minutes of starting the
stenting procedure; these symptoms could be controlled
until its conclusion in three patients. In the fourth patient,
however, the symptoms were so severe that immediate
balloon deflation was necessary before aspiration, rendering
the procedure unprotected. The final patient lost conscious-
ness instantaneously upon balloon inflation, prohibiting
further use of the device. Thus, balloon intolerance is a
system-immanent disadvantage that may prohibit system
use or render it ineffective in about 2% of cases. Conclusive
factors predictive of balloon intolerance have not yet been
established. With the present availability of filter systems for
neuroprotection during CAS (12), interventionists may
convert to such a device in cases of balloon intolerance.
Neurologic complications. Major neurologic events re-
lated to the intervention were observed in three study
patients (3.1%). This incidence is lower, yet not statistically
significantly so, than that reported for CAS procedures
performed without neuroprotection (1–3). Yadav et al. (1)
encountered eight periprocedural strokes and one death in
107 consecutive patients treated between March 1994 and
November 1995, for a major procedure-related complication
rate of 7.5%. In a global survey of 4,757 patients investi-
gated by the end of September 1999 at 36 centers, 200
strokes and 41 procedure-related deaths were reported, for a
combined stroke/death rate of 5.1% (2). Roubin et al. (3)
recently published an update of their previous study (1); they
encountered 38 nonfatal strokes (7.2%) and five deaths
(1.0%) in 528 consecutive patients. The lack of a statistical
significance of the difference in incidence between our study
and those mentioned may be due to a type-2 statistical error
(low number of patients). However, it may also indicate
that, on an intent-to-treat basis, there may actually be no
reduction in the major neurologic complication rate associ-
ated with balloon-protected versus unprotected CAS. This
is apparently supported by our finding in two patients that
“mere,” and ultimately futile, attempts at cannulating the
target artery or placing the protective device distal to the
lesion can result in major neurologic complications.
The American Heart Association guidelines for carotid
endarterectomy recommend intervention in symptomatic
patients with ipsilateral lesions 70% angiographic diame-
ter stenosis, if the stroke morbidity and mortality rate can be
kept below 6%, and in asymptomatic patients with 60%
diameter reduction, if the interventional risk of major
complications can be kept below 3% (13). The stroke rates
observed for symptomatic and asymptomatic patients in this
study (4.6% and 1.9%, respectively) were well within these
limits.
Study limitations. This study was not randomized and
therefore lacked a control group of patients. Quantitative
angiography was not used to measure lesion length and
diameter stenosis. No objective evaluation of embolic events
by means of computed tomography or magnetic resonance
imaging was performed. Histology of aspirated debris has
not been routinely performed in this study; this aspect has
been addressed in a previous report on a subgroup of
patients (14).
Conclusions. It is concluded that use of the GuardWire
temporary balloon-occlusive system as an adjunct to CAS is
feasible in most patients, with a 5.4% overall incidence of
periprocedural neurologic complications and a 3.1% major
and minor stroke rate. Adverse neurologic reactions to
balloon occlusion may prohibit effective use of the system in
about 2% of patients. Superiority of balloon-protected CAS
over previously reported unprotected CAS could not be
demonstrated with statistical significance and may warrant a
larger comparative trial.
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